Chronic effects of anti-Alzheimer's drug, Galantamine hydrobromide on cholinergic system of mice brain

Berchtold, 1998, Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s, Neurobiol Aging, 19, 173, 10.1016/S0197-4580(98)00052-9 Giacobini, 2002, Long term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer's disease, J Neural Transm Suppl, 62, 181, 10.1007/978-3-7091-6139-5_17 Sano, 2002, Prevention of Alzheimer's disease: where we stand, Curr Neurol Neurosci Rep, 2, 392, 10.1007/s11910-002-0064-8 Wenk, 2003, Neuropathologic changes in Alzheimer's disease, J Clin Psychiatry, 9, 7 2007, List of memory enhancing drugs, Drugs, 1, 21 Lanni, 2008, Cognition enhancers between treating and doping the mind, Pharm Res, 57, 196, 10.1016/j.phrs.2008.02.004 2007, Donepezil, rivastigmine, Galantamine, Neurology, 21, 11 Behringer, 1973, 120 Sweeney, 1990, Effects of different doses of Galantamine, a long-acting cholinesterase inhibitor, on memory in mice, Psychopharmacology (Berl), 102, 191, 10.1007/BF02245921 Morris, 1984, Developments of a water-maze procedure for studying spatial learning in the rat, J Neurosci Methods, 11, 47, 10.1016/0165-0270(84)90007-4 Metcalf, 1957 Augustinsson, 1957 Ellman, 1961, A new and rapid calorimetric determination of acetylcholinesterase activity, J Biochem Pharmacol, 7, 88, 10.1016/0006-2952(61)90145-9 Pillai, 1968 Maurice, 1998, Sigma receptor agonists and neurosteroids attenuate β25-35-amyloid peptide-induced amnesia in mice thorough a common mechanism, Neuroscience, 83, 413, 10.1016/S0306-4522(97)00405-3 Chun, 2007, The role of tau phosphorylation and cleavage in neuronal cell death, Front Biosci, 12, 733, 10.2741/2097 Farlow, 2001, Pharmacokinetic profiles of current therapies for Alzheimer's disease: Implications for switching to Galantamine, Clin Ther, 23, A13, 10.1016/S0149-2918(01)80164-8 Bentue-Ferrer, 2003, Clinically Significant drug interactions with cholinergic inhibitors, CNS Drugs, 17, 947, 10.2165/00023210-200317130-00002 Coyle, 2001, Galantamine, a cholinergic inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease, Biol Psychiatry, 49, 289, 10.1016/S0006-3223(00)01101-X Aarsland, 2003, Cognitive, psychiatric and motor response to Galantamine in Parkinson's disease with dementia, Int J Geriatr Psychiatry, 18, 937, 10.1002/gps.949 Loy, 2006, Galantamine for Alzheimer's disease and mild cognitive impairment, Cochrane Database Syst Rev, 25, CD001747 Barnes, 2000, Neuroscience, 99, 17, 10.1016/S0306-4522(00)00180-9 Levin, 2002, Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory, Neuroscience, 109, 757, 10.1016/S0306-4522(01)00538-3 Ballard, 2005, Cholinesterases: roles in the brain during health and disease, Curr Alzheimer Res, 2, 307, 10.2174/1567205054367838 Hohnadel, 2007, Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats, Neuropharmacology, 52, 542, 10.1016/j.neuropharm.2006.08.025 Ji, 2007, Post-ischemic continuous administration of Galantamine attenuates cognitive deficits and hippocampal neurons loss after transient global ischemia in gerbil, Neurosci Lett, 416, 92, 10.1016/j.neulet.2007.01.053 Lorrio, 2007, Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils, J Pharmacol Exp Ther, 322, 591, 10.1124/jpet.107.122747 Lee, 2007, A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia, J Psychopharmacol, 21, 421, 10.1177/0269881106070996